Humacyte (HUMA) Long-Term Investments (2020 - 2021)

Humacyte (HUMA) reported Long-Term Investments of $100.0 million for Q2 2021, little changed quarter-over-quarter from $100.0 million in Q1 2021.

Humacyte (HUMA) Long-Term Investments (2020 - 2021) Analysis & Trends

Humacyte (HUMA) has 2 years of Long-Term Investments data on file, last reported at $100.0 million in Q2 2021.

Long-Term Investments for Q2 2021 came in at $100.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $100.0 million (changed N/A YoY), and the FY2020 annual result was $100.0 million, changed N/A from the prior year.
Long-Term Investments steadied at $100.0 million in Q2 2021 per HUMA's latest filing, from $100.0 million in the prior quarter.
Over five years, Long-Term Investments peaked at $100.0 million in Q2 2021 and troughed at $100.0 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Humacyte	183.21 Mn	134.67 Mn	-1.54 Mn	-

Download Data